Safety and efficacy of three trypanocides in confirmed field cases of trypanosomiasis in working equines in The Gambia: a prospective, randomised, non-inferiority trial by Raftery, Alexandra G. et al.
RESEARCH ARTICLE
Safety and efficacy of three trypanocides in
confirmed field cases of trypanosomiasis in
working equines in The Gambia: a
prospective, randomised, non-inferiority trial
Alexandra G. RafteryID1*, Saloum Jallow2, Jean Rodgers3, David G. M. SuttonID1
1 The Weipers Centre Equine Hospital, Large Animal Clinical Science and Public Health, School of
Veterinary Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow,
United Kingdom, 2 Gambia Horse and Donkey Trust, Sambel Kunda, Central River District, The Gambia,
3 Institute of Biodiversity, Animal Health & Comparative Medicine, College of Medical, Veterinary & Life
Sciences, University of Glasgow, Glasgow, United Kingdom
* a.raftery.1@research.gla.ac.uk
Abstract
Background
Globally, working equines have a continued and growing socioeconomic role in supporting
the livelihoods of between 300–600 million people in low income countries which is rarely
recognised at a national or international level. Infectious diseases have significant impact on
welfare and productivity in this population and equine trypanosomiasis is a priority disease
due to its severity and prevalence. Strategies are required to improve the prevention, diag-
nosis, management and treatment of trypanosomiasis in equines and more data are
required on the efficacy and safety of current trypanocidal drugs.
Methods
A prospective randomised, open-label non-inferiority trial was performed in The Gambia on
horses and donkeys that fulfilled 2/5 clinical inclusion criteria (anaemia, poor body condition,
pyrexia, history of abortion, oedema). Following randomised trypanocidal treatment (dimina-
zene diaceturate, melarsomine dihydrochloride or isometamidium chloride), animals were
observed for immediate adverse drug reactions and follow-up assessment was performed
at 1 and 2 weeks. Blood samples underwent PCR analysis with specific Trypanosoma sp.
primers. Treatment efficacy was assessed by measuring changes in clinical parameters,
clinicopathological results and PCR-status post-treatment after evaluating for bias. Using
PCR status as the outcome variable, non-inferiority of isometamidium treatment was deter-
mined if the upper bound limit of a 2-sided 95% CI was less than 10%.
Results
There was a significant beneficial effect upon the Trypanosoma sp. PCR positive population
following trypanocidal treatment for all groups. The findings of clinical evaluation and PCR
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status supported a superior treatment effect for isometamidium. Melarsomine dihydrochlor-
ide efficacy was inferior to isometamidium. There were immediate, self-limiting side effects
to isometamidium in donkeys (26%). Diminazene had the longest duration of action as
judged by PCR status.
Conclusions
The data support the continued use of isometamidium following careful dose titration in don-
keys and diminazene for trypanosomiasis in equines using the doses and routes of adminis-
tration reported.
Author summary
Equine trypanosomiasis is endemic in many areas of the world with high morbidity and
mortality in affected populations. Trypanocides form an essential part of current treat-
ment strategies but evidence regarding efficacy in equines is scarce. In order to inform
disease management, the efficacy of three trypanocidal drugs was assessed in horses and
donkeys that fulfilled 2/5 clinical inclusion criteria for trypanosomiasis in The Gambia.
Selected equines received randomised treatment with either isometamidium, diminazene
or melarsomine dihydrochloride and were observed for adverse drug reactions. Follow-up
was performed at 1 and 2 weeks. Blood collected at each timepoint was analysed for Try-
panosoma spp. using a PCR approach. Within the selected population 66% were PCR pos-
itive pre-treatment for Trypanosoma spp.. Trypanosome positive individuals responded
favourably to each treatment, but clinical evaluation and PCR status post-treatment sup-
ported a superior effect for isometamidium. Melarsomine dihydrochloride had inferior
efficacy to isometamidium. Immediate adverse side effects were only documented follow-
ing isometamidium administration in donkeys (26%) and these were self-limiting. Dimin-
azene had the longest duration of action as judged by PCR status. The data support the
continued use of isometamidium and diminazene but not melarsomine dihydrochloride
for trypanosomiasis in equines at the doses and routes of administration reported.
Introduction
Working equines are an essential component of infrastructure, maintaining the health and
welfare of between 300 and 600 million people globally, often within the most vulnerable com-
munities [1]. Working equines are relied upon for transport and traction [2], contribute signif-
icantly to household income [3–5] and create opportunities for women and children [4,6]. The
FAO (2014) [7] estimates the world equine population (mules, donkeys and horses) to be just
over 127 million and approximately 85% in low income countries like The Gambia [8]. Inter-
national acknowledgment of the positive impact of working equines upon poverty reduction,
gender equality and environmental stability [9,10] has refocused attempts to tackle the myriad
of issues such as infectious diseases which are known to compromise their welfare and produc-
tivity [1,9–11].
Prevalent diseases such as trypanosomiasis, piroplasmosis and African horse sickness have
the greatest impact upon working equines due to their geographical distribution across lower
income countries. Equine trypanosomiasis has been highlighted as a priority disease for which
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strategies are required to improve diagnosis, management and treatment [10]. Equine try-
panosomiasis is caused by protozoan parasites of the genus Trypanosoma and encompasses
three disease syndromes with overlapping clinical signs. These syndromes are clinically
defined by the mode of transmission which also determines their geographical distribution
[12]. Nagana (Trypanosoma vivax, Trypanosoma congolense and/or Trypanosoma brucei sub-
species) is transmitted by the tsetse fly (Glossina spp.); Surra (T. b. evansi) is mechanically
transmitted by biting flies, and Dourine (T. b. equiperdum) is venereally transmitted [12].
The Gambia is typical of countries situated within the tsetse belt with respect to the mix of
equine species, routine husbandry and concurrent disease and management problems [13–
18]. Equine trypanosomiasis is hyperendemic within this region [19–22] and mortality is high
[17]. Trypanocidal treatment efficacy and safety in equines is currently poorly understood due
to a predominant focus on livestock trypanosomiasis and available studies do not take into
account species-specific effects or pharmacokinetics [23–35].
The aim of this study was to determine the field efficacy and safety of three widely used try-
panocides; isometamidium, diminazene and melarsomine dihydrochloride in horses, donkeys
and mules in The Gambia. The study showed that the response to trypanocidal treatment var-
ied significantly depending not only on the trypanocidal drug used but also on the infective
species of trypanosome present.
Methods
Recruitment of study animals
Subjects were recruited at two time points (November; 2012 and 2013) from 10 villages in the
Central River District in The Gambia. At each village, recruitment was via a one day mobile
veterinary clinic. All owners were invited to present their equines either for a free health check
or because of pre-existing health concerns. Equines presenting were examined by an experi-
enced equine vet (AR, DS). A detailed history was obtained via Gambia Horse and Donkey
Trust staff acting as translators. Age was estimated from dentition [18], body condition (0-5/5)
was scored [18,36] and body weight (kg) was estimated using a validated nomogram [36–38].
A 6 ml jugular blood sample was taken via direct venepuncture for measurement of haemato-
crit (HCT %) and total plasma protein (TP g/l). Excess blood was stored in EDTA, initially at
4˚C. For animals subsequently included in the treatment trial, 0.2 ml of whole blood was
placed upon a Whatman FTA Classic card, as a contingency for lost or damaged whole blood
samples, and the remainder of the EDTA blood tube was stored at -20˚C for later PCR analysis.
Excess blood was discarded after measurement of HCT and TP if the animal was not included
in the study.
Animals were included in the study if at least two of five clinical inclusion criteria were ful-
filled: body condition score�1.5/5, HCT�24%, temperature horse>38.5˚C, donkey
>37.8˚C, limb or ventral oedema and a history of abortion at any time prior to the study
period. Animals were excluded if they had a concurrent debilitating condition, a primary pre-
senting sign of neurological disease or had received trypanocidal treatment in the previous
month. A debilitating condition was defined as a concurrent severe condition such as a long
bone fracture or severe soft tissue injury likely to result in death or necessitate euthanasia dur-
ing the study period. Information about previous trypanocidal treatment was acquired from
the owner of the animal.
Enrolment and treatment
Verbal informed consent was obtained from the owner for inclusion in the study. A microchip
with a unique identifying number was placed in the mid third of the nuchal ligament at the
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time of inclusion. The animal received a randomised treatment (melarsomine dihydrochlor-
ide, diminazene, or isometamidium) using simple randomisation that was concealed from
those enrolling animals onto the study. At the time of the study, all three of the trypanocides
were in common use in that region for treatment of equine trypanosomiasis and there was no
clinical evidence to support superiority of one trypanocidal drug compared to another, or an
increased risk of administration to a particular subgroup.
After treatment the animal was observed for any immediate side effects such as type 1
hypersensitivity reactions or acute toxicity. A summary of drugs and routes of administration
is detailed in Table 1. Due to differences in gross appearance and route of administration of
the trypanocides the investigators could not be blinded to the treatment received but follow up
examinations were blinded to prior treatment allocation.
Drugs were sourced directly from the pharmaceutical company or from a verified reputable
supplier at the described dosages and administration routes.
Animals were re-examined at 1 and 2 weeks post-treatment, and history, clinical examina-
tion and blood sampling were repeated. If clinical response to treatment had been poor [two
out of three of anaemia� 24%, pyrexia (horse >38.5˚C, donkey>37.8˚C) or dull demeanour
still present] the treatment was repeated with a different trypanocide (isometamidium or if
used previously, diminazene) at the time of the second re-examination.
Sample processing
Centrifugation (SpinCrit Centrifuge) of micro-haematocrit capillary tubes was used to mea-
sure the HCT. TP was measured on plasma using a hand held refractometer (Sinotech N-style)
that had been pre-calibrated with sterile deionised water.
DNA extraction
Genomic DNA was extracted from the whole blood samples using QIAamp DNA Blood Maxi
Kit (QIAGEN) following manufacturer’s instructions [39] [with the substitution of 50 μl Pro-
teinase K (20 mg/ml) for the supplied Qiagen Protease]. The purified DNA was eluted from
the column in a volume of 600 μl Buffer AE. In the absence of whole blood samples, genomic
DNA was extracted from the Whatman FTA cards using the QIAamp DNA Micro Kit (QIA-
GEN) for gDNA extraction [40]. To compensate for the uneven distribution of trypanosomes
across a blood spot on an FTA card [41] 3 extractions each using 3 x 2mm punches were taken
from each card to determine the infective status for each sample. For a given individual the
same type of sample was used for each time point.
PCR analysis
To confirm that the extracted DNA was of suitable quality for PCR analysis the assay was per-
formed employing an equine specific (Equus ferus caballus or Equus africanus asinus) primer
pair targeting a highly conserved equine cytochrome b sequence [42].
To detect Trypanosoma spp. DNA, primers [43] targeting the multicopy number satellite
DNA located on the mini chromosomes, were selected due to the high sensitivity and
Table 1. Summary of the doses and routes of administration selected for the three trypanocides.
DRUG TRADE NAME COMPOUND DOSE (MG/KG) ROUTE OF ADMINISTRATION CONCENTRATION (%)
DIMINASAN Diminazene diaceturate 3.5 mg/kg I.M. split into two aliquots one in each rump; using a 20g 1.5 inch needle. 5%
CYMELARSAN Melarsomine dihydrochloride 0.25 mg/kg I.V. 19g 1.5 inch needle. 0.5%
SAMORIN Isometamidium chloride 0.5 mg/kg I.V. 19g 1.5 inch needle 0.5%
https://doi.org/10.1371/journal.pntd.0007175.t001
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specificity. The Trypanosoma sp. and subspecies of interest were selected based upon previous
surveys indicating their presence in this region [19,20]. These primers, Trypanosoma congo-
lense Savannah (TCS 1 and 2), Trypanosoma brucei sp. (TBr1 and 2) and Trypanosoma vivax
West (TVW1 and 2) are the current gold standard diagnostic as recommended by the OIE
[44] and sequence details are provided in Table 2.
PCR amplification was conducted in a total reaction volume of 25 μl comprising 2.5 μl
template DNA, 1 x HP buffer, 0.25 mM dNTPs, 1.5mM MgCl2, 0.01 μg/μl Fw primer, 0.01
μg/μl Rv primer and 1.25U Taq Thermo Hotstart. Positive and negative controls were used
to minimise the probability of false positive or negative results. Positive controls were stock
samples of laboratory strains (T. b. brucei GVR35; T. congolense gifted L.M., T. vivax gifted
L.M.). PCR was then performed. For all primer pairs amplification was initiated by a single
cycle of 95˚C for 15 min. This was followed by denaturation at 94˚C for 15 s, annealing
(temperature dependent on primer pair) for 30 s and extension at 94˚C for 90 s. Primer spe-
cific cycling parameters used are detailed in Table 1. In each case a final extension at 72˚C
for 10 min was incorporated.
Following amplification, for each sample 10 μl of PCR product was loaded on to a 2% aga-
rose gel (SeaKem) containing 1 μg/ml ethidium bromide. 5 μl of 100 bp ladder (Invitrogen)
was used to assess the PCR product size. The electrophoresis was performed for 45 min at
150V in 1 x TBE buffer prior to examination and imaging in a UV transilluminator.
PCR analysis for concurrent haemoparasite infection
The samples from week one (initial examination) were also screened by nested PCR with a
modified Babesia/Theileria 18s catch-all primer set [45–47]. Reaction conditions were an ini-
tial denaturation at 94˚C for 5 min, followed by 30 cycles of 94˚C for 45 s, annealing at 67˚C
(external primers) or 57˚C (internal primers) for 60 s, elongation at 72˚C for 60 s, with a final
extension at 72˚C for 5 min. A 1:10 dilution of the primary reaction product was used as a tem-
plate for the secondary reaction.
A subsection of the week 1 samples (n = 60) was screened by nested PCR for Anaplasma sp.
using a catch all primer set [48]. Reaction conditions were an initial denaturation at 94˚C for 5
min, followed by 30 cycles of 94˚C for 30 s, annealing at 65˚C (external primers) or 64˚C
(internal primers) for 30 s, elongation at 72˚C for 60 s, with a final extension at 72˚C for 5
min. A 1:10 dilution of the primary reaction product was used as a template for the secondary
reaction.
Interpretation of clinical and clinicopathological data
Species specific reference ranges were identified for body temperature (donkey 36.2–37.8;
horse 37.7–38.5˚C), heart rate (donkey 40–53; horse 24–40 beats per min) and respiratory rate
(donkey 16–20; horse 6–16 breaths per min) [49,50]
Species specific reference values for HCT for horses (31–43%) [51] and donkeys (27–42%)
[52] from UK equine populations were selected since there are no endemic infectious diseases
resulting in anaemia.
Statistical analysis
Sample size calculations for non-inferiority analysis were based upon the most recent pub-
lished prevalence data for Trypanosoma spp. available for the region [19] and previous pub-
lished efficacy for the two drugs anticipated to have the least disparity based upon available
literature (diminazene, isometamidium).
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Assuming a treatment success of 100% (isometamidium)[23] and 82% (diminazene)
[17,18,28] with a two- sided significance (α) of 0.05 and a power of 0.8 ((P = 1-ß); ß = 0.2) a
total of 14 animals positive for each Trypanosoma sp. was required [53,54]. To ensure repre-
sentation of all three pathogenic Trypanosoma spp. (i.e. to ensure 14 positive of each Trypano-
soma sp.) the total required group size was increased to 78 (assuming 18% positive for T.
brucei sp. in population presenting for treatment [19]). Assuming 30% may be lost to follow
up a minimum of 100 animals was required to be recruited on week 1.
Rstudio was used for statistical analysis. Normality testing was performed with the Shapiro-
Wilk test. Median and inter-quartile range were reported for numerical non-parametric data,
mean and standard deviation for parametric data. The Wilcoxon signed rank test was used for
comparison of paired non-parametric data and the Wilcoxon rank sum test for independent
non-parametric data. The Kruskal-Wallis test was used to compare more than two groups of
non-parametric data. Chi-squared test was used to compare two proportions of categorical
data or the Fischer’s exact test where group size was small (difference less than 5). For compar-
ison of paired proportions, the McNemar test was used. The level of significance was set as
p�0.05.
Non-inferiority analysis was used to determine treatment efficacy as outlined by the FDA
for clinical trials [55] with PCR status as the outcome variable. As the most frequently used try-
panocide within The Gambia, isometamidium was selected as the control drug. M1 (the differ-
ence between the control drug and a placebo controlled study) was estimated at 60% from a
previous study which had assessed the effect of using isometamidium as prophylaxis compared
to no treatment [24]. A value of 10% was selected for M2 (the accepted difference between the
control drug and a test drug) based upon clinical experience and previously published treat-
ment trials [56]. For each Trypanosoma sp. (T. vivax, T. congolense, T. brucei sp.), at each time
point (week 2, week 3), the difference (%) in achieving a positive outcome between the control
drug and the test drug (point estimate) and 95% confidence intervals were calculated. The
analyses were repeated on a whole animal basis defining treatment success as PCR negative for
all Trypanosoma spp. following treatment. Each analysis was visualised on a forest plot.
Ethics statement
Ethical approval for this study was granted by the University of Glasgow School of Veterinary
Medicine ethics committee (reference 21a/13), The Donkey Sanctuary ethics board and the
Gambian Ministry of Agriculture. The study abided by the Veterinary Surgeons Act 1966 (this
was the criteria used by the committee), procedures were performed by a veterinary surgeon
and the procedures were of direct benefit to the animal (diagnostic blood samples) and so the
study did not come under Animals (Scientific Procedures) Act 1986. Verbal consent was
obtained from the owner for inclusion in this study and documented on the dedicated form.
Results
Animals from the whole treated population (n = 254) that were positive on PCR for at least
one Trypanosoma sp. (n = 162) were used to assess the relative treatment efficacy of the three
selected trypanocides (Fig 1).
Baseline parameters
Baseline history, signalement, subjective and objective clinical examination findings and clini-
copathological results for the treatment trial population (n = 162) were comparable between
treatment groups (p>0.05) and are summarised in supplementary data (S1 Table). A quiet
demeanour was common in individuals with Trypanosoma sp. infection (84/162; 52%); smaller
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numbers were assessed as dull (34/162; 21%) or bright (32/162; 20%). Oedema was an uncom-
mon finding (6/162; 4%) in infected individuals but tachycardia was extremely common (124/
162; 77%). Within the female population previous abortion, occurring at any time prior to pre-
sentation, was commonly reported (21/94; 22%), with no difference between treatment groups.
This was representative of the sampled population (60/340; 18% of female equines) (p = 0.3). A
history or clinical evidence of diarrhoea was found in 7/162 (4%) of animals which was repre-
sentative of the sampled population (17/639; 3%) (p = 0.3). All animals were positive for at
least one Trypanosoma sp. [T. congolense (110/162; 68%); T. vivax (80/162; 49%) or T. brucei
sp. (38/162; 23%)] and co-infection was common (52/162; 32%). More than half of the animals
(90/162; 56%) were also positive for piroplasmosis, the proportion did not differ between treat-
ment groups (p>0.05). None of the tested animals were positive for anaplasmosis (0/60; 0%).
Treatment effect on clinical parameters
Subjective parameters. In the treatment trial population (n = 162) there was a general
improvement in the assessed demeanour following treatment (Fig 2A) with a greater number
of bright animals (68/141; 48%) and fewer dull animals (6/141; 4%) in week 3 compared to
week 1 (p<0.001). A significantly greater effect on demeanour was noted for isometamidium
and diminazene at week 2 compared to melarsomine dihydrochloride (p = 0.007), but this dif-
ference was no longer evident by week 3 (p = 0.26) (S4 Table). There was also a general
improvement in the assessed body condition score following treatment (p = 0.003) (Fig 2B).
Fig 1. Flow chart illustrating recruitment of equines to the treatment study. Of the 254 animals which fulfilled clinical
criteria for inclusion in the study, 162 subsequently proved PCR positive for at least one Trypanosoma sp. and were included in
the treatment trial (n = 162). Animals that were PCR negative for all Trypanosoma sp. at the first examination were excluded
from the treatment trial (n = 85). Adverse drug reactions were documented for the whole treated population (n = 254). Animals
which fulfilled the clinical criteria for which PCR status was known (n = 247) were used to document the number of new or
recrudescence of existing infections within treatment groups. Colours correspond to treatment group (blue = melarsomine,
yellow = isometamidium, green = diminazene), exclusion (grey) or loss to follow up (dark grey) of animals.
https://doi.org/10.1371/journal.pntd.0007175.g001
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The median body condition score prior to treatment was 1.5/5 (IQR 1–2) with an increase to
2/5 (1.5–2) by week 3 and this did not vary significantly between treatment groups (p = 0.47).
Objective clinical parameters. A significant decrease (Fig 3) in rectal temperature (˚C)
over the treatment period was apparent in all groups (week 1 to week 3; p<0.001) but there
were no differences between treatment groups. There was no significant change in heart rate
or respiratory rate following treatment and values above reference range remained common
post-treatment (S2 Table).
Treatment effect on clinicopathological parameters
There was a significant (p<0.001) increase in haematocrit over the treatment period from pre-
(week 1) to post-treatment (week 2 and week 3) for the whole treatment group. The median
HCT prior to treatment was 20% (16–23), 23% (20–26) at week 2 and 25% (22–28) at week 3.
Treatment with melarsomine dihydrochloride resulted in a smaller increase in HCT (3% (0–
6)) (p = 0.025) than isometamidium (6% (2–10)) or diminazene (5% (1–10)) (Fig 3; Table 3).
Total plasma protein (TP g/l) increased significantly (p<0.001) from a median of 82 g/l
(74–90) to 95 g/l (87–105) by week 2, remaining elevated at week 3 (96 g/l (87–105) (Table 3).
There was no significant difference in response between treatment groups.
Fig 2. Bar plots illustrating categorisation of subjective parameters for the treatment trial population (n = 162). Demeanour (A) and body
condition score (B) were evaluated during the initial examination (week 1) and follow up post-treatment evaluations (weeks 2 and 3). Number of
individuals (frequency) is plotted on the y-axis in each case. Bar plots represent the whole treatment trial population at each time point (week 1,
week 2 and week 3). Demeanour (A) was assessed as BAR (bright, alert and responsive), QAR (quiet, alert and responsive) or dull. Assessed
demeanour improved following treatment (week 1 to week 2) (p<0.001). Body condition (B) score (0-5/5) improved following trypanocidal
treatment (p = 0.003).
https://doi.org/10.1371/journal.pntd.0007175.g002
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Fig 3. Scatterplots illustrating the change in clinical parameters from week 1 to 3. A. Scatterplot showing individual changes in rectal temperature for whole
treatment trial population (n = 162) following treatment. The regression line is marked in blue with 95% confidence intervals in dark grey. Light blue background
shading illustrates animals presenting with parameters within reference range. B. Scatterplot showing individual changes in HCT, with colour coding to illustrate
trypanocidal treatment group (melarsomine dihydrochloride = blue, diminazene = red and isometamidium = green) for whole treatment trial population
(n = 162) following treatment. The regression line colour represents the trypanocide with 95% confidence intervals shown in dark grey. Presenting degree of
anaemia (%) calculated by the difference between the animal’s HCT and the lower end of species appropriate reference values (donkey 27%; horse 31%).
https://doi.org/10.1371/journal.pntd.0007175.g003
Table 3. Clinicopathological parameters.
WEEK 1 WEEK 2 WEEK 3
PARAMETER Cy
n = 58
Dim
n = 51
Iso
n = 53
Cy
n = 54
Dim
n = 48
Iso
n = 49
Cy
n = 50
Dim
n = 44
Iso
n = 45
HAEMATOCRIT
(%)
Horse 20
(19–24)
20
(13–
24)
20
(15–
23)
22
(20–23)
24
(19–
27)
24
(21–
27)
22
(18–23)
22
(20–
28)
28
(24–
28)
�30% 20/21
(95%)
16/16
(100%)
18/18
(100%)
21/21
(100%)
14/15
(93%)
16/17
(94%)
18/18
(100%)
10/11
(91%)
13/15
(87%)
Donkey 20
(16–24)
20
(16–
23)
20
(16–
23)
22
(20–26)
23
(21–
27)
23
(21–
26)
23
(21–25)
26
(23–
28)
26
(22–
28)
�26% 37/37
(100%)
32/35
(91%)
34/35
(97%)
25/33
(76%)
24/33
(73%)
25/32
(78%)
27/ 32
(84%)
19/33
(58%)
18/30
(60%)
TOTAL
PROTEIN (G/L)
Horse 80
(70–90)
77
(70–
87)
88
(76–
92)
90
(82–100)
84
(80–
93)
96
(88–
105)
96
(81–103)
81
(78–
93)
100
(93–
104)
Donkey 82
(75–90)
82
(75–
90)
80
(75–
87)
98
(86–105)
96
(90–
105)
98
(90–
105)
100 (92–
106)
96
(87–
106)
95
(90–
106)
Haematocrit (%) and total plasma protein (g/l) for the whole treatment population (n = 162) subdivided by
trypanocidal drug group (melarsomine dihydrochloride (Cy), diminazene (Dim), isometamidium (Iso) are presented
by species (horse and donkey) and time point (week 1, 2 and 3). Parameters are presented as median and IQR and
categorised as within or outside the reference range (proportion and percentage).
https://doi.org/10.1371/journal.pntd.0007175.t003
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Treatment effect on Trypanosoma sp. PCR status
Demonstration of treatment effect. The selected trypanocidal agents caused a significant
decrease in the proportion of PCR positive animals for Trypanosoma congolense, T. vivax and
T. brucei sp. in the whole treatment trial population (p<0.001) (S3 Table, Fig 4). The reduction
in PCR positive animals was not statistically significant (p>0.05) at week 2 or 3 for T. congo-
lense and T. vivax or week 3 for T. brucei sp. in the melarsomine dihydrochloride group.
Non-inferiority analysis of comparative trypanocidal efficacy
Comparison of diminazene to isometamidium. At week 2 diminazene was non-inferior
to isometamidium for treatment of T. congolense infections. By week 3 diminazene was infe-
rior to isometamidium as evidenced by PCR status. For T. vivax at week 2, non-inferiority of
diminazene to isometamidium was not demonstrated. By week 3 diminazene treatment was
Fig 4. Bar chart lattice illustrating Trypanosoma spp. PCR status at each time point for each drug. Treatment trial group (n = 162) are
subdivided by trypanocidal drug (Cy = melarsomine dihydrochloride, Dim = diminazene, Iso = isometamidium), time period (week 1, 2 or 3) and
infective Trypanosoma spp. (T. brucei sp., T. congolense or T. vivax). ^ Denotes no significant change (p>0.05) in PCR status from week 1.
Isometamidium demonstrated a comparable effect (94–100% reduction in PCR positive status) to that reported in previous studies [24,25]. This
validates the use of isometamidium for use as the control drug for non-inferiority analysis to compare the outcome to trypanocidal treatment based
on PCR status.
https://doi.org/10.1371/journal.pntd.0007175.g004
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non-inferior to isometamidium. For T. brucei sp. at week 2, the wide confidence intervals led
to inconclusive results with respect to inferiority. At week 3 non-inferiority of diminazene was
not demonstrated but could not be excluded (lower 95% CI < 0%) (Fig 5A; S5 Table).
Comparing melarsomine dihydrochloride to isometamidium. For T. congolense at
week 2, isometamidium was superior to melarsomine dihydrochloride. The results did not
Fig 5. Forest plots illustrating non-inferiority analysis of the outcome of trypanocidal treatment by Trypanosoma
spp.. Trypanosoma spp. PCR status was used as the outcome variable. The control drug (Iso = isometamidium) was
compared to test drugs (Dim = diminazene (a) and Cy = melarsomine dihydrochloride (b)) for each infective species
of Trypanosoma spp. at each time point (week 2 and 3). Positive treatment outcome was defined as a negative PCR
result. The percentage difference in treatment outcome is presented as a point estimate (blue square) and two sided
95% confidence intervals (blue bars). Results are divided by Trypanosoma spp. (Brucei = T. brucei sp.; Congo = T.
congolense; Vivax = T. vivax) and time point (week 2 and week 3). The 10% line represents M2, the accepted difference
between drugs to demonstrate non-inferiority. The 60% line represents M1, the accepted difference between the
control drug and the test drug to demonstrate placebo effect. a) Isometamidium (control drug) is compared to
diminazene (test drug) b) Isometamidium (control drug) is compared to melarsomine dihydrochloride (test drug).
https://doi.org/10.1371/journal.pntd.0007175.g005
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support a difference between melarsomine dihydrochloride and placebo administration (M1
value). At week 3 isometamidium was superior to melarsomine dihydrochloride and the effect
of melarsomine dihydrochloride was equivalent to less than placebo administration (M1
value). For T. vivax at week 2 and 3, isometamidium was superior to melarsomine dihy-
drochloride, and the results could not support a difference between melarsomine dihy-
drochloride and placebo administration. For T. brucei sp. at week 2 non-inferiority of
melarsomine dihydrochloride was not demonstrated but could still be plausible (lower 95%
CI < 0%). At week 3 isometamidium was superior to melarsomine dihydrochloride and a
comparable efficacy of melarsomine dihydrochloride to placebo could not be excluded (Fig
5B; S6 Table).
Whole animal PCR status. As mixed trypanosome infections were common, whole ani-
mal outcome was measured via PCR status. At week 2 diminazene demonstrated non-inferior-
ity to isometamidium. By week 3 the point estimate favoured isometamidium and non-
inferiority of diminazene was not demonstrated (Fig 6A). At week 2 isometamidium was supe-
rior to melarsomine dihydrochloride and the results could not support a difference between
melarsomine dihydrochloride and placebo administration. At week 3 isometamidium was
superior to melarsomine dihydrochloride and melarsomine dihydrochloride had an effect
comparable to placebo (Fig 6A; S7 Table).
New and recrudescing infection rate
The whole treated population for which PCR results were available (n = 247) was evaluated
(Fig 1). For the purpose of this analysis, new or recrudescing infections were defined as a posi-
tive PCR result at week 2 or 3 in an individual animal that was PCR negative on week 1 for
that Trypanosoma sp. A total of 28 new or recrudescing infections occurred, the greatest num-
ber of new PCR positives occurred in the melarsomine dihydrochloride treated animals (10/
87; 12%), and the fewest number of new PCR positives in the diminazene treated animals (1/
85; 1%) (Fig 7).
Fig 6. Forest plots illustrating non-inferiority analysis of the outcome of trypanocidal treatment by whole animal. Forest plots illustrating non-
inferiority analysis of control drug and test drug for whole animal (n = 162). a) Control (isometamidium) vs test (diminazene) b) Control
(isometamidium) vs test (melarsomine dihydrochloride). Positive treatment outcome was defined as a negative PCR result for all Trypanosoma spp.
The percentage difference in treatment outcome was presented as a point estimate (blue square) and two-sided 95% confidence intervals (blue bars).
Results are presented as whole animal Trypanosoma spp. status by PCR and are divided by time point (week 2 and week 3). The 10% line represents
M2, the accepted difference between drugs to demonstrate non-inferiority. The 60% line represents M1, the accepted difference between the drugs to
demonstrate effect comparable to placebo.
https://doi.org/10.1371/journal.pntd.0007175.g006
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Adverse effects
The whole treated population (n = 254) was used to document adverse reactions to the
trypanocides.
Immediate effects. There were no immediate adverse effects noted in horses. Immediate
adverse effects were only noted in donkeys in the isometamidium treatment group (12/47 don-
keys; 26%) (Fig 8A). The reactions ranged from mild to severe and occurred almost immedi-
ately following injection of the drug. No additional treatment was required as the parameters
normalised over 45–60 minutes.
In the majority of these donkeys a pain response was observed (n = 9) immediately follow-
ing injection. This was indicated by the animal scratching at its neck, snorting, tongue playing,
tail swishing or displaying transient colic signs including rolling. These signs were transient
and resolved within 5–10 minutes. Clinical signs of shock developed after treatment in 4 ani-
mals, with one severe reaction resulting in cold extremities, pale mucous membranes, pro-
found tachycardia (84-130bpm), and increased respiratory effort and rate (100 breaths per
minute). These signs gradually resolved and lasted for up to 1 hour. A characteristic skin reac-
tion with generalised sweating and a linear sweating pattern over the neck and face associated
Fig 7. Tree maps illustrating the number of new PCR positive animals during the study period within the whole study population
(n = 247). The new positives are subdivided by trypanocidal treatment (Cy = melarsomine dihydrochloride, Dim = diminazene,
Iso = isometamidium) and Trypanosoma sp (T. congolense = pink, T. brucei sp. = pale blue, T. vivax = purple). A. Tree map illustrating new PCR
positives during week 2 (n = 15). B. Tree map illustrating new PCR positives during week 3 (n = 13).
https://doi.org/10.1371/journal.pntd.0007175.g007
Safety and efficacy of three trypanocides for trypanosomiasis in equines
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007175 March 22, 2019 14 / 24
with ’skin wrinkling’ was observed in 5 animals (Fig 8A). One animal passed faeces shortly fol-
lowing injection and also displayed signs of the skin reaction.
Delayed effects. Information collected from the owners regarding any concerns following
treatment after treatment together with abnormalities detected on clinical examination at
weeks 2 and 3 are summarised in Fig 8B. Diarrhoea (n = 9) was self-limiting without evidence
of hypovolaemia or systemic inflammatory response syndrome. Injection site reactions were
mild and included perivascular reaction and/or haematoma (isometamidium and melarso-
mine dihydrochloride) and palpable intra-muscular swelling (diminazene). None were painful
on palpation and all had resolved at the end of the study period. Abortion was owner reported
and information on stage of gestation was limited.
Discussion
This study is the first to provide a thorough, multi-faceted and comparative evaluation of the
efficacy and safety of trypanocidal treatment in equines with confirmed Trypanosoma sp. (T.
vivax, T. congolense and/or T. brucei sp.) infections, thus providing important information for
development of control programs and a robust model for future field trials of trypanocides.
A positive clinical effect was documented in response to all the trypanocidal treatments.
The observed positive response in demeanour and body condition score was similar between
treatment groups supporting a reducing parasite burden in all groups. Weight loss in trypano-
somiasis is due to a combination of reduced feed intake and impaired efficiency of feed con-
version [57]. Although two weeks is a short time frame for significant body mass increase to
Fig 8. Acute and delayed adverse drug reactions occurring after trypanocidal administration in working equines. a) Acute drug
reactions were only seen in donkeys. Photographs illustrate characteristic linear sweating pattern and ’skin wrinkling’ observed in
immediate reaction to isometamidium documented in 12/47 (26%) of treated donkeys. b) Delayed adverse reactions were seen in
donkeys and horses. These are summarised in the table subdivided by treatment group.
https://doi.org/10.1371/journal.pntd.0007175.g008
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occur [58], the documented improvement in body condition is consistent with an improved
appetite, increased feed intake and intestinal fill. The median body condition score (2/5)
remained poor at the final evaluation reflecting the magnitude of the disease burden and
multi-morbidities such as piroplasmosis, lameness [11] and poor nutrition facing this popula-
tion. A subdued demeanour has been previously reported as an indicator of acute disease
onset in equines [24] secondary to pyrexia, anaemia and presence of an inflammatory
response. Following trypanocidal drug treatment a large proportion of the population
remained ’quiet’ and did not warrant assessment as ’bright’; this may reflect incomplete resolu-
tion of disease and the potential presence of co-morbidities such as piroplasmosis.
Fever has been identified as a reliable indicator for the onset of acute Trypanosoma spp.
infection [24] but in chronic disease this may be a less consistent finding [24]. In the present
study there was a significant decrease in rectal temperature, most marked in animals originally
febrile, following chemotherapy. Fever remained common (33%; 47/139) in this population
post-treatment but whether this represents ongoing disease, a persistent inflammatory
response due to treatment, the presence of a co-infection, the high ambient temperature or a
combination of factors requires further investigation. With improved demeanour some of the
animals became more challenging to handle which could have contributed to persistent
tachypnoea (61%; 86/140) and tachycardia (74%; 105/142) two weeks after treatment.
Isometamidium and diminazene were the most effective of the three trypanocides in the
amelioration of anaemia, but melarsomine dihydrochloride also had a positive effect. Anaemia
is a major contributor to morbidity in trypanosomiasis; control of anaemia has been suggested
to be more important than control of parasitaemia [59] in treating the disease phenotype.
Physiological haematocrit increase is limited by the rate of erythrocyte regeneration; estimated
in horses at 0.672% per day [60] which is equivalent to an increase of 9.4% over this 14 day
study period. This is comparable to the maximal increase in HCT measured in the isometami-
dium treated horses investigated in this study. For isometamidium, the continued improve-
ment over the two weeks after treatment supports a sustained effect in resolving or
substantially reducing the mechanisms of anaemia, seen to a lesser extent for diminazene and
isometamidium treated donkeys. The short duration of action of melarsomine dihydrochlor-
ide reported in other species [61] is consistent with the small increase in HCT detected at week
2 post-treatment with no further increase noted at week 3 in this treatment group. For all treat-
ment groups it is also important to consider that the presence of concurrent diseases including
piroplasmosis could contribute to the residual anaemia.
Trypanocidal treatment generates a marked inflammatory response. Total plasma protein
increased in all treatment groups markedly by the first week of follow up (week 2). Differen-
tials for hyperproteinaemia include dehydration (pan hyperproteinaemia) or hyperglobulinae-
mia. Clinical evaluation did not identify widespread evidence of severe dehydration however
the substantial buffy coats noted following centrifugation of the blood would support a marked
post-treatment inflammatory response and exacerbation of the pre-existing hyperglobulinae-
mia [62–64]. Since immune evasion through antigenic variation is key to parasite survival
[65], treatment with a trypanocide would be expected to generate an inflammatory response as
these mechanisms are then impaired. However the duration and impact of this resulting
inflammatory response are unknown.
The Trypanosoma spp. infection status (determined by PCR) provided the greatest differenti-
ating factor between the trypanocides in this study. The efficacy of melarsomine dihydrochlor-
ide for treatment of T. congolense in this population was comparable to placebo and was inferior
to isometamidium for treatment of T. brucei sp. and T. vivax. Melarsomine dihydrochloride
was also of limited efficacy in preventing new infections following treatment. Given the high
challenge in the area and apparent short duration of activity a repeated dosing regimen may be
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more appropriate when using this drug. The results of this study indicate that the use of melar-
somine dihydrochloride at this dose, frequency and route of administration in regions with a
heavy, mixed Trypanosoma spp. burden cannot be recommended for treatment of equine infec-
tions. Melarsomine dihydrochloride is licensed in camels for treatment of T. b. evansi [30]
where improved tissue penetration [66] may carry treatment benefits not assessed by this study.
Diminazene was non-inferior to isometamidium for treatment of T. vivax infections but
not for T. congolense or T. brucei sp.. In equines the pathogenicity of T. vivax is speculated to
be low and therefore this may be of minimal clinical significance [19]. In this population it was
not possible to extract information to corroborate these observations due to the complex co-
infection profile. On a whole animal basis (which accounts for co-infection status) there was
no evidence from the PCR analysis that the use of isometamidium should be substituted for
diminazene or melarsomine dihydrochloride.
The immediate reaction to isometamidium in donkeys was the most significant adverse
reaction. A low therapeutic index and dose-dependent toxicity [67] related to an anticholines-
terase effect [68] has been documented in other species, producing similar signs. The adverse
reaction is associated with decreased serum cations (calcium, magnesium, sodium and potas-
sium) [69] consistent with third space losses and occasional deaths have been reported in cattle
[70]. The small stature of donkeys could render them more vulnerable to over-estimation of
body weight. The dose selected for this study was the lowest used in equines [23–25]. Inter-
specific differences in tolerance are also possible as drug metabolism varies between equines
[35]. In this study although no animal died and the reactions were transient, the clinical signs
were severe. At the current time, in the absence of alternative therapeutics, pre-treatment of
donkeys with an parasympatholytic agent such as buscopan, atropine or glycopyrrolate may
ameliorate adverse signs [71]. This is corroborated by experimental studies [72]. Division of
the drug dose into two fractions given an hour apart, or reducing the total dose could both
decrease the occurrence of adverse effects if they are related to peak plasma concentration. The
use of intramuscular isometamidium administration was discounted in equines due to
reported associated severe muscle necrosis [69]. Further work is required to investigate isome-
tamidium pharmacokinetics in equines. The prevalence of adverse effects was otherwise low.
Due to a high baseline prevalence of diarrhoea (17/639; 3%) and abortion (60/340; 18% of
female equines) in this population, both of which are also reported clinical signs of trypanoso-
miasis, interpretation of other potential adverse responses to treatment requires caution.
There have been no previous associations between the trypanocides used in this study and
these clinical signs and their safety in pregnancy has been evaluated in other species with no
evidence of increased risk (isometamidium [70], diminazene [73] and melarsomine dihy-
drochloride [61,74]). Previous studies have raised concerns regarding the use of diminazene in
equines [26] especially donkeys where development of central nervous signs had been reported
[75]. The current study suggests that diminazene can be used safely in equines at the lower
dose of 3.5mg/kg i.m., but re-evaluation of higher doses may be useful in relation to T. brucei
sp. treatment prior to onset of neurological signs.
New or recrudescing Trypanosoma spp. infections were more common in the isometami-
dium group than the diminazene group indicating shorter residual activity. Isometamidium is
typically thought to have a long duration of activity even when given intra-venously due to
prolonged release from secondary depots (mean elimination half-life is 135hrs in cattle) [76].
This has not been confirmed in equines but was supported here by the continued reduction in
the number of post-treatment PCR positive animals from week 2 to week 3. New or recrudesc-
ing infections could indicate resistance [23] or differing pharmacokinetics in equines. Dimina-
zene has a similar reported elimination half-life (74hrs [77] - 200 hrs [78]) to intravenous
isometamidium in cattle and efficacy for up to 3 weeks [79]. The low new infection rate present
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in the diminazene group could support a sustained effect in equines. For diminazene, new
infections were restricted to T brucei sp. consistent with the higher required therapeutic dose
(7mg/kg) for this parasite [79]. These results challenge the use of a ’sanative pair’ [80] approach
in equines due to evidence of a shorter residual activity of isometamidium. Melarsomine dihy-
drochloride does not have any reported residual activity [61] and this is consistent with the
highest rates of new infection observed in this group.
Limitations to the current investigation include the significant levels of variation present
within the population when field cases are studied. Randomisation of treatment groups sought
to minimise bias therefore starting parameters for the three treatment groups were similar. A
placebo group would have been beneficial to account for varying parameters in waxing and
waning chronic disease, but ethically this could not be justified. The high prevalence of piro-
plasmosis present in the region could also have complicated interpretation of post-treatment
clinical signs as diminazene is known to have efficacy against piroplasms [81]. There are also
limitations associated with utilising a non-quantitative PCR to assess infections post-treatment
as changes in parasitaemia are only detected if they cross the threshold of detection. Positive
results could also occur due to drug resistance (intrinsic/ acquired), inappropriate drug dose
or dosing interval. The PCR assay used in this study does not differentiate between viable and
non-viable Trypanosoma sp. DNA which is particularly pertinent following trypanocidal treat-
ment. For parasites with significant tissue burdens (T. vivax and T. brucei sp.[82–84]) parasi-
taemia may be an insensitive marker of clinical effect leading to false negatives. Furthermore
the presence of non-viable trypanosome DNA persisting in the sample following trypanocidal
drug administration could give rise to a positive PCR reaction and lead to a false assessment of
the level of drug resistance within the population.’
In conclusion, analysis of the treatment response on clinical evaluation, clinicopathological
results and molecular diagnostics support the continued use of isometamidium as a first line
trypanocide within this population with diminazene recommended as a second choice but
question the use of a ’sanative pair’ [80] approach in equines. Further investigation into the
pharmacokinetics and duration of action of isometamidium when given intravenously to
equines (horses, mules and donkeys) is necessary. The use of melarsomine dihydrochloride is
not recommended in this region at this dose, frequency and route of administration. These
observations highlight the importance of a multi-faceted approach to disease control as the
rate of new infections is high. Currently the biggest limitation on equine trypanosomiasis
treatment in this region of The Gambia is not drug efficacy but the absence of a coordinated
approach. Before novel therapeutics are trialled it is essential that these problems are
addressed; sporadic, non-targeted use in this environment will favour development of drug
resistance. In the short term, coordination of large scale equine trypanocidal treatment contig-
uous with treatment of cattle may be beneficial.
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